Kabir Olaniran: Sickle Cell Trait and Chronic Kidney Disease Risk
Kabir Olaniran, Principal Investigator, Sickle Cell Kidney Biorepository of UT Southwestern Medical Center, shared a post on LinkedIn about his recent article, published in CJASN, adding:
“Sickle cell trait has long been designated ‘a benign carrier state’. For the kidney, that label no longer holds.
CJASN invited me to write the editorial on a study by Cai et al (PMID: 41758580) which used metabolomics to provide insights into sickle cell trait kidney injury. In this editorial, I take stock of where the field now stands.
The epidemiology is consistent: a 1.5 to 2 fold independent risk of chronic kidney disease and kidney failure across diverse cohorts. The mechanisms of kidney injury are starting to come into focus from four independent directions: proteomic, microRNA, epigenetic, and metabolomic.
These platforms converge on the same pathways of oxidative stress and nitric oxide dysregulation. This is coherent with the localized renal medullary injury described in sickle cell trait, a condition biologically distinct from sickle cell anemia, and is now supported by a validated murine model.
That convergence has brought the field to a threshold. A carrier population of 300 million worldwide and approximately 3 million in the United States, a plausible organ-specific pathophysiology, and converging multiomic and preclinical evidence justify dedicated, prospective studies spanning childhood through adulthood.
The molecular picture is maturing. The infrastructure to act on it is what we must build next.”
Title: The Metabolomic Landscape of Sickle Cell Trait Nephropathy
Author: Kabir Olaniran
Stay updated with Hemostasis Today.
-
Sep 17, 2026, 15:33Alexandros Makis: When Microcytic Anemia Has an Inherited Cause
-
Sep 17, 2026, 15:22α2-Antiplasmin Inhibition and the Future of Thrombolysis
-
Sep 17, 2026, 15:20Fatma M. Attia: Expanding the Evidence Base for Therapeutic Plasma Exchange Across Multiple Indications
-
Sep 17, 2026, 15:19Conan McIlwrath: The Haemophilia Society Engages With IBCA
-
Sep 17, 2026, 15:06Eleftheria Hatzimichael: A Contemporary Diagnostic Approach to Inherited Microcytic Anemias
-
Sep 17, 2026, 14:51Konstantin Yenkoyan: Emicizumab and the Power of Translational Science
-
Sep 17, 2026, 14:47Zachary Sutton: Translating the 2026 KDIGO Guideline Into Practice
-
Sep 17, 2026, 14:43Leah Williams: Evaluating Medical Device Haemocompatibility Under ISO 10993-4
-
Sep 17, 2026, 14:32Ria Ahuja: Scaling Evidence-Informed Anemia Interventions Through Training